Preferred Label : Mutant-selective EGFR Inhibitor PF-06459988;
NCIt related terms : PF-06459988;
NCIt definition : An orally available, small molecule, third-generation, irreversible inhibitor of epidermal
growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity.
EGFR inhibitor PF-06459988 specifically binds to and inhibits mutant forms of EGFR,
including the secondary acquired resistance mutation T790M, which prevents EGFR-mediated
signaling and leads to cell death in EGFRm-expressing tumor cells. Compared to some
other EGFR inhibitors, PF-06459988 may have therapeutic benefits in tumors with T790M-mediated
drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR),
and does not cause dose-limiting toxicities that are seen with the use of non-selective
EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated
in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.;
UNII : 5IE92SK9EB;
CAS number : 1428774-45-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1428774-45-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : PF-06459988;
Origin ID : C119624;
UMLS CUI : C3896788;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
